IMMX Immix: Accounting Value per Share

Graphic logo of Immix (IMMX)

The net book value per share reflects the internal resource dynamics of Immix Biopharma, Inc. (IMMX), with the latest value recorded as 3.17. Immix Biopharma, Inc. (IMMX) is implementing green chemistry principles for safe waste disposal. The brand possesses significant potential in developing targeted oncology treatments. However, high micro-cap volatility and the anticipation of new clinical trials starting create substantial speculative risks.

IMMX: Immix Biopharma, Inc. Net Asset Value per Share 07/04/2022 - 10/27/2026

Immix Biopharma Inc. - analytical breakdowns and key metrics (IMMX)

- price and consensus price forecast:
Price Chart Immix|IMMX - Consensus Target
- market capitalization data:
Market Valuation Immix Biopharma, Inc.|IMMX - Business Value
- book capitalization data:
Net Assets per Single Share Immix Biopharma|IMMX - Total Stockholders' Equity|Market Value to Book Value Ratio immixbio.com|IMMX - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Immix Biopharma, Inc.|IMMX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Immix|IMMX - Company Cumulative Debt|Debt to Book Capitalization Ratio Immix Biopharma, Inc.
Fundamental company valuation:IMMX - immixbio.com
Flagship merchandise of Immix

Book value per share reflects the portion of net assets attributable to a single security, allowing for an assessment of the business's actual tangible value relative to market quotes. An analysis of the historical book value per share reveals the capitalization rates of Immix Biopharma, Inc. (IMMX), where a diversified portfolio of immunotherapy developments for various pathologies mitigates the risk of asset impairment in the event of potential failures in individual clinical trials.

Competitor analysis for Immix Biopharma, Inc.

IBRX: Net Assets per Single Share|Immunocore Corp (IMCR) - Accounting Value per Share|Accounting Value per Share Janux Therapeutics|RCUS (arcusbio.com) - Equity per Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|HOWL: Accounting Value per Share|ALXO - Net Asset Value per Share|Accounting Value per Share Cue Biopharma, Inc. (CUE)|PDSB - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx